In recent years, studies have shown that immunotherapy targeting programmed cell death ligand‐1 (PD‐L1) combined with platinum‐based chemotherapy has shown an superior outcome of the overall survival (OS) in patients with extensive‐stage SCLC (ES‐SCLC) [5]. This evidence concerns the gene CD274 and small cell lung carcinoma.